Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The California Cancer Consortium completed a phase I trial of E7389 (eribulin mesylate), an analog of the marine natural product halichondrin B. This trial was to determine the pharmacodynamics, pharmacokinetics, and MTD of E7389 administered by bolus injection weekly for 3 weeks out of four.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Cancer Chemother. Pharmacol.

Title: Cancer chemotherapy and pharmacology

Publisher: Springer Nature

ISSN (Electronic): 1432-0843

ISSN (Print): 0344-5704

Publication date (Electronic): Nov 2015

Volume: 76

Issue: 5

Affiliations

[1 ] Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Rd., Duarte, CA, 91010, USA. rmorgan@coh.org.

[2 ] Department of Cancer Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA.

[3 ] Department of Biostatistics, City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA.

[4 ] Division of Medical Oncology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, 90033, USA.

[5 ] Division of Medical Oncology, University of California, Davis Cancer Center, Sacramento, CA, USA.

[6 ] Eisai Research Institute, Andover, MA, 01810, USA.

[7 ] Edward P. Evans Foundation, Casanova, VA, 20139, USA.

[8 ] Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, 20892, USA.

[9 ] Stanford Cancer Center, Stanford, CA, 94305, USA.

[10 ] Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Rd., Duarte, CA, 91010, USA.

[11 ] Division of Cancer Treatment and Diagnosis6, National Cancer Institute, Bethesda, MD, 20892, USA.

Article

Publisher Item ID: 10.1007/s00280-015-2868-7 Mid ID: NIHMS722710

DOI: 10.1007/s00280-015-2868-7

PMC ID: 4694049

PubMed ID: 26362045

SO-VID: 810fb33e-de32-44b1-a95f-5d867b95ecec

History

Keywords: Halichondrin B analog,Eribulin,Phase I trial,Pharmacokinetics,Pharmacodynamics

Data availability:

Keywords: Halichondrin B analog, Eribulin, Phase I trial, Pharmacokinetics, Pharmacodynamics

Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.

Read this article at

Abstract

Related collections

Dermal Microdialysis in Pharmacokinetics

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 96

Cited by 13